Daily Biotech Movers — 2026-08-11: The Reversal Tape — Crash Bounces Meet a Dilution-Financed Leaderboard

Tuesday, August 11, 2026 was the morning after Monday’s -90% clinical-failure day — and the tape did what reversal tapes do: it bounced the two destroyed names and found fresh victims elsewhere. 320 names finished higher and 240 lower across 560 directional moves among 581 tracked companies — a 1.33-to-1 advance ratio, the second consecutive day of positive breadth — with a median move of +0.55%, a mean of +0.59%, and a standard deviation of 5.65%. The broad market was a hair negative (SPY -0.32%, XLV -0.26%, IBB -0.14%, XBI +0.03%), so the small-cap biotech tape modestly outperformed on a day when nothing in the index moved. 101 names were anomaly-flagged (a move of at least 5% or volume at least 2x normal), and 87 of those moved at least 5% on price.

The leaderboard inverted Monday’s story. Sionna Therapeutics (+13.33%) and Tenax Therapeutics (+17.82%) — the two names that lost ~90% on August 10 — both bounced on heavy volume, textbook oversold-reversal prints with no new information. The destruction moved to a new cohort, and this time the mechanism was different: the day’s three biggest losers were all capital-structure events, not data events. PDS Biotechnology (-64.87%) de-prioritized its lead program in a strategic refocus; Curis (-36.89%) filed a registered offering on the back of a sliding tape; Silexion Therapeutics (-31.00%) priced a $2.5 million offering at a 56% discount. On the upside, the winners were equally thematic: Alamar Biosciences (+30.65%) converted an 82% revenue beat into a new 52-week high, NeOnc Technologies (+24.29%) ran into a Wednesday Phase 2a readout, and Alector (+23.67%) extended the post-earnings re-rating that began August 6. The pattern: capital rotating out of event-risk names into earnings-validated and pre-data positions, with dilution — not failed data — as the day’s dominant downside mechanism.

The Distribution

Measure	August 11 reading
Tracked / priced	581
Directional moves	560
Up / down	320 / 240
Mean / median	+0.59% / +0.55%
Standard deviation	5.65%
Anomaly-flagged	101
Price moves of at least 5%	87

Breadth was positive for a second session (1.33 advancers per decliner) and the median was a touch above zero — the center of the tape was quietly firm. The dispersion (5.65% stdev) remained elevated but is down from Monday’s 7.47%, consistent with a settling tape: Monday’s two -90% crashes were not repeated, and no single print dominates the day’s variance the way SION and TENX did. The index read was flat-to-negative across the board, which makes the up-close more notable: biotech breadth was positive on a day when the S&P 500 fell 0.32%. Sector leadership confirms the rotation was selective rather than broad — Devices - Implants (+3.63% average, +6.54% median across 10 names) and Stem Cells/Cellular Therapy (+1.91%, n=24) led, while Psychedelics (-1.69%), Devices - Imaging (-1.43%), and Generic Drugs (-1.39%) lagged.

The 6 Classes of Mover Signal

On August 11, three of the six top movers are capital-structure events (one strategic refocus, two financings), one is a fresh earnings catalyst, one is anticipatory pre-positioning, and one is a post-earnings continuation — with the day’s most violent prints all landing on the downside.

1. Halt-release or reverse-split-adjacent. No top-six print is a clean Class 1 event today. The closest mechanical analogs sit mid-board: TENX (+17.82% at $1.62) and SION (+13.33% at $5.10) are the mirror image of Class 1 — post-crash reversal prints rather than post-split prints — with Monday’s -90% collapses as the prior-cycle event. Both bounced on 6-7x volume with five-day momentum still at -88% to -90%, which is the signature of a dead-cat or value-recovery bid, not a fresh mechanism. JUNS (Jupiter Neurosciences, -11.49%) continued its slide into a prior split action at 0.17x volume — the mechanical low-volume tell.

2. Single-stock clinical or regulatory event. Two of the day’s top winners are Class 2-adjacent. NTHI (NeOnc Technologies, +24.29% on 10.58x volume) is the cleanest anticipatory Class 2 print: topline Phase 2a data for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma is due Wednesday, August 12, and Tuesday’s 10.6x-volume run is the final pre-data positioning leg of a “triple confluence” setup the company itself flagged (Newsfile via stockanalysis — NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence; Business Insider — NeOnc approaches a major biotech inflection point). ALMR (Alamar Biosciences, +30.65%) is a Class 2 fundamental event — a same-morning Q2 report (details below). On the loser side, PDSB is the day’s Class 2 corporate/strategic event: a letter-to-shareholders refocus that the market priced as value-destructive.

3. Buyout or strategic capital. No top-six print is a Class 3 deal event. The closest strategic-capital analog is PDSB’s proposed partnership of PDS0101 — but a “partnership strategy” announced alongside a lead-program de-prioritization is the opposite of a funded deal; the market treated it as capital withdrawal, not capital infusion.

4. Sector rotation. The sector read is a mild, selective risk-on tilt with no dominant theme. Leaders: Devices - Implants (+3.63% avg / +6.54% median across 10 — genuine breadth, with the median well above the average), Cannabis-related (+2.25%, n=5), Stem Cells/Cellular Therapy (+1.91%, n=24), Small Molecule Pharma (+1.15%, n=146). Laggards: Psychedelics & Related (-1.69%, n=5), Devices - Imaging (-1.43%, n=8), Generic Drugs (-1.39%, n=5), Devices - Surgical (-0.84%, n=27). The index trio — XBI +0.03% versus SPY -0.32% — shows small-cap biotech marginally bid while broad healthcare (XLV -0.26%) and the S&P drifted lower; a quiet rotation within biotech toward revenue-positive devices and stem-cell names, not a sector-wide bid.

5. Sell-the-news / prior-cycle profit-taking. Three of the six top movers carry prior-cycle or financing signatures. ALEC (Alector, +23.67%) is a continuation of the August 6 Q2-beat re-rating — no fresh August 11 company news (H.C. Wainwright actually trimmed Q3 estimates the same morning), with 5d momentum of +35.7% confirming the move was already underway. Flagged as prior-cycle continuation, not a fresh same-day catalyst. CRIS (Curis, -36.89%) is a fresh-filing dilution event layered on a multi-session unwind of the July 22 emavusertib data spike (5d -51.1%). SLXN (Silexion, -31.00%) is a deep-discount financing print with 5d -45.5% — the market had been sliding into the deal for a week. SION and TENX’s bounces are also Class 5-flavored: prior-cycle crashes, today’s reversals carry no new information.

6. Stealth accumulation / distribution. One stealth print on the board: KYMR (Kymera Therapeutics, +0.96% on 3.65x volume, 5d +5.0%) — 2.38 million shares on an essentially flat day for a $109 stock, the highest-information unresolved signal on the tape. With 5d momentum positive and the price holding flat, the lean is accumulation-leaning — institutional flow in a protein-degradation leader without a price tell. Watch for resolution over the next one to three sessions.

Top 3 Winners — What Drove Them

ALMR — Alamar Biosciences — +30.65% on 5.72x volume

Alamar closed at $36.57 on 1,558,687 shares — 5.72x its 30-day average — at a new 52-week high, with five-day momentum of +34.9%, after reporting Q2 2026 results on August 11: revenue rose 82% year over year and gross margin expanded on a stronger mix of higher-margin consumables for the NULISA proteomic platform (Tech Star — ALMR shares surge 31% as consumables lift gross margin; MarketBeat — ALMR Q2 2026 earnings report; GuruFocus via Yahoo — ALMR Q2 earnings call highlights). The April 2026 IPO name converted a growth story into a margin story in one session — instruments seeding the installed base, consumables driving the reorder economics — and the 5.72x volume confirms institutional follow-through rather than a thin-float pop (MarketBeat — ALMR reaches new 12-month high after earnings beat). Signal class: Class 2 single-stock fundamental (Q2 revenue/margin beat), fresh same-day catalyst.

NTHI — NeOnc Technologies — +24.29% on 10.58x volume

NeOnc closed at $4.35 on 1,068,228 shares — 10.58x its 30-day average — with five-day momentum of +26.8%, as traders positioned ahead of topline Phase 2a data for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma expected Wednesday, August 12 (Newsfile via stockanalysis — NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence; FinancialContent — NTHI Phase 2a data expected). The setup is the classic pre-readout run into a binary event: a tight float, an 8-K/10-Q filed the prior session, and a data date the market knows (Business Insider — NeOnc approaches a major biotech inflection point). Tuesday’s +24% on 10.6x volume is anticipatory, not confirmatory — the binary event itself lands Wednesday, and the 10x volume means the position was built the day before the readout. Signal class: Class 2 single-stock clinical pre-positioning ahead of a binary readout.

ALEC — Alector — +23.67% on 6.20x volume

Alector closed at $2.09 on 5,543,351 shares — 6.20x its 30-day average — with five-day momentum of +35.7%, the strongest leg of a re-rating that began with its August 6 Q2 report: EPS of -$0.21 versus -$0.23 consensus and revenue of $3.32 million versus $1.71 million consensus, with management highlighting progress across the Alector Brain Carrier (ABC) blood-brain-barrier platform and lead ABC-enabled anti-amyloid program AL137 (TheFly — Alector reports Q2 EPS (21c), consensus (23c); GlobeNewswire — Alector reports Q2 2026 financial results). No fresh August 11 company news drove Tuesday’s print — H.C. Wainwright actually trimmed Q3 estimates that morning (MarketBeat — HC Wainwright issues negative outlook for Alector earnings) — so the move reads as a continuation/short-cover leg of the post-earnings re-rating of a name still recovering from the July 8 GSK partnership termination (Reuters — Alector and GSK partnership to end after drug failures; MSN — Alector stock plummets 13% as GSK terminates neuroscience pact). Signal class: Class 2 fundamental (Q2 beat), continuation leg — flagged as not a fresh same-day catalyst.

Top 3 Losers — What Drove Them

PDSB — PDS Biotechnology — -64.87% on 22.27x volume

PDS Biotech collapsed to $0.26 on 28,273,565 shares — 22.27x its 30-day average — with five-day momentum of -64.3%, after issuing a Letter to Shareholders on August 11 announcing a strategic refocus that de-prioritizes the late-stage Versamune/PDS0101 program (a “partnership strategy”) in favor of PDS0301, an investigational tumor-targeted IL-12 immunocytokine, in metastatic colorectal cancer, with a randomized Phase 2b designed around FDA feedback (GlobeNewswire — PDS Biotech announces strategic refocus prioritizing PDS0301 in mCRC; stockanalysis.com — PDSB news). The market read the pivot as abandoning the company’s most advanced asset for an earlier-stage one — a value-destructive pipeline restructuring priced in a single session at 22x volume, with a prior 13.32M-share resale registration (TheFly — PDS Biotech registers to sell 13.32M shares for holders) and Q2 financials due August 13 compounding the pressure. The after-hours bounce to $0.27 was negligible. Signal class: Class 2 single-stock strategic event (pipeline refocus), fresh same-day catalyst.

CRIS — Curis — -36.89% on 5.91x volume

Curis fell to $2.31 on 600,817 shares — 5.91x its 30-day average — with five-day momentum of -51.1%, after the company filed a registration statement on August 10 to sell 3.73 million shares of common stock and warrants, with A.G.P./Alliance Global Partners and Laidlaw & Company acting as placement agents (TheFly via TipRanks — Curis files to sell 3.73M shares of common stock, warrants; stockanalysis.com — Curis registration filing). The financing registration lands on a tape already sliding from the post-spike unwind of July 22’s positive emavusertib (TakeAim Lymphoma) data and the TakeAim CLL enrollment milestone (PRNewswire — Curis doses first five patients in TakeAim CLL study; TheFly — Curis price target raised to $43 at H.C. Wainwright). New dilution on top of an already-sliding tape is the day’s cleanest “sell the financing” print: 5.91x volume, five days of -51%, and a registered offering the market did not want. Signal class: Class 5 prior-cycle/dilution financing (registered offering), fresh filing dated August 10.

SLXN — Silexion Therapeutics — -31.00% on 12.28x volume

Silexion fell to $1.03 on 2,030,582 shares — 12.28x its 30-day average — with five-day momentum of -45.5%, after pricing a $2.5 million public offering of 3,846,161 ordinary shares and series E warrants at a combined $0.65 per share — a ~56% discount to the prior close — with H.C. Wainwright as exclusive placement agent and closing expected August 13 (GlobeNewswire via Finviz — Silexion announces pricing of $2.5M public offering; Business Insider — Silexion announces pricing of $2.5M public offering; MarketChameleon — SLXN press releases). The proceeds fund the SIL204 clinical trial in KRAS-driven cancers, but the terms — a $0.65 offering price against a $1.49 prior close, with warrants doubling the overhang — repriced the story in one session at 12x volume. The market had already been sliding into the deal (5d -45.5% after the August 4 SIL204 update and the S-1 filing), and Tuesday’s close embeds the dilution terms announced after the bell. Signal class: Class 5 dilution financing (deep-discount public offering), fresh same-day pricing.

The Cross-Cutting Pattern

Tuesday’s pattern is a two-sided capital-structure tape on a quietly positive breadth day: the two -90% clinical failures of Monday bounced on no new information, while the day’s real destruction moved to names being repriced by dilution and restructuring — and the upside was claimed by earnings-validated and pre-data positions. PDSB (-64.87%), CRIS (-36.89%), and SLXN (-31.00%) are not data failures; they are capital events — a pipeline refocus, a registered offering, a deep-discount placement. That is a materially different risk mix from Monday, when the two biggest losers were binary clinical endpoints. The asymmetry is the durable signal: three of the six top movers lost roughly a third to two-thirds of their value on financing and restructuring mechanics alone, with no clinical data in sight.

The bounce of SION (+13.33%) and TENX (+17.82%) frames the day. Both names lost ~90% on August 10 on failed clinical programs; both opened Tuesday and bought back roughly 15% of the damage on 6-7x volume. These are technical reversals — no new data, no new financing, no new guidance — and the five-day momentum columns (still -88% to -90%) show how much value destruction the bounces are trying to absorb. When a tape bounces its most-destroyed names while simultaneously destroying three new names on capital mechanics, it is telling you something about where the risk premium sits: biotech capital is not fleeing the sector (breadth was positive), it is rotating out of event-risk and financing-risk names into names with validated revenue (ALMR), imminent data (NTHI), or post-earnings momentum (ALEC).

The sector data supports the selective-risk read. XBI (+0.03%) marginally outperformed SPY (-0.32%) while XLV (-0.26%) and IBB (-0.14%) were flat — no sector bid, but no sector dump either. Devices - Implants (+3.63% average, +6.54% median) had genuine breadth, and Stem Cells/Cellular Therapy (+1.91%, n=24) showed a broad second pocket of strength. And the stealth tape deserves one line: KYMR’s 3.65x volume on a +0.96% day with 5d of +5.0% is the most accumulation-leaning unresolved signal on the board — a $109 protein-degradation leader quietly absorbing 2.4 million shares.

The 5 Data Points That Matter

1. % change vs sector mean. The winners beat their sectors by double digits — ALMR +30.65% against a proteomics/diagnostics tape at +0.66%, NTHI +24.29% against a small-molecule-heavy board at +1.15% — while the losers defined the downside: PDSB’s -64.87% sits in no sector average (the refocus is company-specific), and CRIS (-36.89%) and SLXN (-31.00%) dragged the small-cap end of the tape. Every print that mattered was idiosyncratic; sector averages mostly reflect the Devices - Implants bid and the PDSB/CRIS drag on the microcap categories (Nanotechnology’s -14.81% average is a 3-name artifact).

2. Volume ratio. The loser volume was extreme: PDSB 22.27x on 28.3 million shares and SLXN 12.28x on 2.0 million — plus DRMA at 25.97x and MREO at 23.99x mid-board — meaning entire floats changed hands on the day’s destruction. NTHI’s 10.58x on the winner side is the defining institutional-pre-positioning number; ALEC’s 6.20x confirms the continuation leg is being fed; ALMR’s 5.72x is a solid, non-parabolic confirmation.

3. 5-day momentum. The three losers were multi-session slides that accelerated into Tuesday: PDSB -64.3%, CRIS -51.1%, SLXN -45.5% — none is a one-day event. The winners were the opposite: ALMR +34.9% and ALEC +35.7% 5d both exceed their daily prints (continuation), while NTHI’s +26.8% 5d on a +24.29% day shows the run built almost entirely in the last two sessions (pre-data). SION and TENX at -89.8%/-88.3% 5d on +13.33%/+17.82% bounces are the mechanical tell that the reversals are absorbing, not reversing, the crashes.

4. 52-week range. ALMR at $36.57 printed a fresh 52-week high — the only breakout on the board. ALEC at $2.09 is still in the bottom third of its range after the GSK-termination collapse, its +23.67% a recovery leg, not a breakout. PDSB at $0.26, CRIS at $2.31, and SLXN at $1.03 all sit at or near multi-year lows — the financing cohort repriced to distressed levels. NTHI at $4.35 is mid-range ahead of its binary Wednesday readout.

5. Cash / dilution context. The losers are liquidity stories: PDSB is de-prioritizing its lead program because capital allocation demanded it, with Q2 cash disclosure due August 13; CRIS added a 3.73M-share offering to an already-diluted cap table; SLXN’s $0.65 pricing (56% below close) with warrants attached is the textbook distressed-financing term sheet. On the upside, ALMR’s 82% revenue growth and margin expansion bought the strongest currency in biotech right now — self-funding trajectory — while NTHI runs its binary event with a thin float and ALEC’s re-rating is happening on a shrinking cost base.

What This Synthesis Will and Won’t Tell You

This synthesis is a one-day reading, and it should be read as such. It tells you what moved and why — the 101 anomaly-flagged names, the six data-defined top movers, the class of signal behind each, and the cross-cutting pattern: on the morning after a -90% clinical-failure day, biotech capital rotated from event-risk into earnings-validated and pre-data positions, and the day’s downside was dominated by dilution and restructuring mechanics rather than failed data. It does not tell you what happens next: NTHI’s Wednesday Phase 2a readout is a genuine binary that will resolve the day’s biggest pre-positioned winner in one direction or the other; ALEC’s continuation can extend or fade into the Q3 estimate cuts; PDSB, CRIS, and SLXN can stabilize at distressed levels or keep sliding; ALMR’s new high can hold or mean-revert.

The honest limits: the why-investigation covers the six data-defined top movers only — mid-board prints elsewhere in the top 15 (Pyxis Oncology -26.11% on 8.40x volume, Fennec +16.82%, Tempest +13.46% on 7.70x, Mereo +12.15% on 23.99x) carry their own stories that are noted but not deep-dived. Sector categories are broad, and small-n buckets (Nanotechnology, n=3; Generic Drugs, n=5; Psychedelics, n=5) should be read with skepticism. And a single day’s median of +0.55% says nothing about the week or the quarter — the durable signal here is the shift in where biotech risk is being destroyed: Monday was clinical; Tuesday was capital-structure. When the tape stops destroying names on data and starts destroying them on financing terms, the marginal biotech investor is demanding cash — and only cash — as the floor.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-08-11 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Sources: GlobeNewswire on PDS Biotech’s strategic refocus; TheFly via TipRanks on Curis’ offering filing; GlobeNewswire via Finviz on Silexion’s offering pricing; Tech Star on Alamar’s Q2 margin beat; MarketBeat on ALMR’s Q2 earnings report; Newsfile via stockanalysis on NTHI’s Phase 2a data expectations; Business Insider on NeOnc’s pre-data setup; TheFly on Alector’s Q2 beat; GlobeNewswire on Alector’s Q2 results; Reuters on the Alector-GSK termination; PRNewswire on Curis’ TakeAim CLL milestone; MarketBeat on HC Wainwright’s Alector outlook.